BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut. 2002;50:196-200. [PMID: 11788559 DOI: 10.1136/gut.50.2.196] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Felipez LM, Gokhale R, Tierney MP, Kirschner BS. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr. 2012;54:28-33. [PMID: 21681114 DOI: 10.1097/mpg.0b013e318228349e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
2 Zhao C, Wang X, Wang J, Hua X, Yao Y. Effect of moxibustion on the expressions of protein KGF-1, KGF-2 and IL-6 in colon of rats with ulcerative colitis. J Acupunct Tuina Sci 2012;10:138-45. [DOI: 10.1007/s11726-012-0590-0] [Reference Citation Analysis]
3 Pan X, Liu JH. Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis. Bioengineered 2021;12:3647-61. [PMID: 34261404 DOI: 10.1080/21655979.2021.1949844] [Reference Citation Analysis]
4 Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003;2:973-85. [PMID: 14654796 DOI: 10.1038/nrd1251] [Cited by in Crossref: 480] [Cited by in F6Publishing: 477] [Article Influence: 26.7] [Reference Citation Analysis]
5 Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002;16:1117-24. [PMID: 12030953 DOI: 10.1046/j.1365-2036.2002.01273.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
6 Campelo SR, da Silva MB, Vieira JL, da Silva JP, Salgado CG. Effects of immunomodulatory drugs on TNF-α and IL-12 production by purified epidermal langerhans cells and peritoneal macrophages. BMC Res Notes 2011;4:24. [PMID: 21276247 DOI: 10.1186/1756-0500-4-24] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
7 Ginsburg PM, Ehrenpreis ED. A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis: THALIDOMIDE FOR MESENTERIC PANNICULITIS. Alimentary Pharmacology & Therapeutics 2002;16:2115-22. [DOI: 10.1046/j.1365-2036.2002.01383.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
8 Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;CD007351. [PMID: 19370685 DOI: 10.1002/14651858.cd007351.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CSJ, Perowne R, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease: LENALIDOMIDE IN ACTIVE CROHN’S DISEASE. Alimentary Pharmacology & Therapeutics 2007;26:421-30. [DOI: 10.1111/j.1365-2036.2007.03385.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
10 Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610. [DOI: 10.1053/j.gastro.2004.02.070] [Cited by in Crossref: 290] [Cited by in F6Publishing: 256] [Article Influence: 16.1] [Reference Citation Analysis]
11 Ng SC, Chan FKL, Sung JJY. Review article: the role of non-biological drugs in refractory inflammatory bowel disease: Review: refractory inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2011;33:417-27. [DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
12 Gerich ME, Yoon JL, Targan SR, Ippoliti AF, Vasiliauskas EA. Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther 2015;41:429-37. [PMID: 25511905 DOI: 10.1111/apt.13057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
13 Chen D. Dually Efficacious Medicine Against Fibrosis and Cancer. Med Sci (Basel) 2019;7:E41. [PMID: 30836705 DOI: 10.3390/medsci7030041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lee C, Kim K, Lee H, Nahm FS, Lim Y, Park J, Kim C. The effect of thalidomide on spinal cord ischemia/reperfusion injury in a rabbit model. Spinal Cord 2007;45:149-57. [DOI: 10.1038/sj.sc.3101931] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mazzon E, Cuzzocrea S. THALIDOMIDE TREATMENT REDUCES THE ALTERATION OF PARACELLULAR BARRIER FUNCTION IN MICE ILEUM DURING EXPERIMENTAL COLITIS. Shock 2006;25:515-21. [DOI: 10.1097/01.shk.0000209556.31457.e7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
16 Zheng CF, Xu JH, Huang Y, Leung YK. Treatment of pediatric refractory Crohn’s disease with thalidomide. World J Gastroenterol 2011; 17(10): 1286-1291 [PMID: 21455327 DOI: 10.3748/wjg.v17.i10.1286] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
17 Srinivasan R, Akobeng AK. Thalidomide and thalidomide analogues for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;CD007350. [PMID: 19370684 DOI: 10.1002/14651858.cd007350.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
18 Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn’s disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res. 2003;47:1-10. [PMID: 12526855 DOI: 10.1016/s1043-6618(02)00264-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
19 Bauditz J. Effective treatment of gastrointestinal bleeding with thalidomide - Chances and limitations. World J Gastroenterol 2016; 22(11): 3158-3164 [PMID: 27003992 DOI: 10.3748/wjg.v22.i11.3158] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
20 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
21 Feng N, Chen H, Fu S, Bian Z, Lin X, Yang L, Gao Y, Fang J, Ge Z. HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide. Sci Rep 2016;6:27280. [PMID: 27249651 DOI: 10.1038/srep27280] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
22 Metz DC, Vakil N, Keeffe EB, Lichtenstein GR. Advances in Gastrointestinal Pharmacotherapy. Clinical Gastroenterology and Hepatology 2005;3:1167-79. [DOI: 10.1016/s1542-3565(05)00895-5] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
23 Bhol KC, Schechter PJ. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig Dis Sci 2007;52:2732-42. [PMID: 17436088 DOI: 10.1007/s10620-006-9738-4] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 5.6] [Reference Citation Analysis]
24 Matthews S, Mccoy C. Thalidomide: A review of approved and investigational uses. Clinical Therapeutics 2003;25:342-95. [DOI: 10.1016/s0149-2918(03)80085-1] [Cited by in Crossref: 136] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
25 Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-palumbo A, Gaudio FD, Turco MC, Petrella A, Maria RD, Stassi G. NF-κB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum 2005;52:2179-91. [DOI: 10.1002/art.21145] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
26 Kamalaporn P, Saravanan R, Cirocco M, May G, Kortan P, Kandel G, Marcon N. Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. Eur J Gastroenterol Hepatol. 2009;21:1347-1350. [PMID: 19730385 DOI: 10.1097/meg.0b013e32832c9346] [Cited by in Crossref: 38] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
27 Gockel HR, Lügering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, Lügering N. Thalidomide Induces Apoptosis in Human Monocytes by Using a Cytochrome c -Dependent Pathway. J Immunol 2004;172:5103-9. [DOI: 10.4049/jimmunol.172.8.5103] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
28 Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727-739. [PMID: 12360276 DOI: 10.1038/nrc905] [Cited by in Crossref: 1113] [Cited by in F6Publishing: 925] [Article Influence: 55.7] [Reference Citation Analysis]
29 Simon M, Pariente B, Lambert J, Cosnes J, Bouhnik Y, Marteau P, Allez M, Colombel JF, Gornet JM. Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease. Clin Gastroenterol Hepatol 2016;14:966-972.e2. [PMID: 26598226 DOI: 10.1016/j.cgh.2015.10.034] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
30 Ng SC. Thalidomide and refractory Crohn's disease: what is in the future? J Clin Gastroenterol 2014;48:476-7. [PMID: 24781387 DOI: 10.1097/MCG.0000000000000136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007;13:5979-84. [PMID: 18023086 DOI: 10.3748/wjg.v13.45.5979] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
32 Wang X, Liu Y, Dong H, Wu L, Feng X, Zhou Z, Zhao C, Liu H, Wu H. Herb-Partitioned Moxibustion Regulates the TLR2/NF-κB Signaling Pathway in a Rat Model of Ulcerative Colitis. Evid Based Complement Alternat Med 2015;2015:949065. [PMID: 26339273 DOI: 10.1155/2015/949065] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
33 Leite MR, Santos SS, Lyra AC, Mota J, Santana GO. Thalidomide induces mucosal healing in Crohn's disease: Case report. World J Gastroenterol 2011; 17(45): 5028-5031 [PMID: 22174554 DOI: 10.3748/wjg.v17.i45.5028] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
34 Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M, Nakano T, Kubo H. Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice. J Immunol 2007;179:708-14. [DOI: 10.4049/jimmunol.179.1.708] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 4.5] [Reference Citation Analysis]
35 Amirshahrokhi K, Ghazi-khansari M. Thalidomide attenuates multiple low-dose streptozotocin-induced diabetes in mice by inhibition of proinflammatory cytokines. Cytokine 2012;60:522-7. [DOI: 10.1016/j.cyto.2012.07.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
36 Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacology & Therapeutics 2010;128:519-48. [DOI: 10.1016/j.pharmthera.2010.08.007] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 11.0] [Reference Citation Analysis]
37 Chidlow JH, Langston W, Greer JJ, Ostanin D, Abdelbaqi M, Houghton J, Senthilkumar A, Shukla D, Mazar AP, Grisham MB. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006;169:2014-2030. [PMID: 17148665 DOI: 10.2353/ajpath.2006.051021] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 6.6] [Reference Citation Analysis]
38 Yu TT, Zhang HJ. Diagnosis and treatment of Crohn's disease complicated by massive lower gastrointestinal hemorrhage. Shijie Huaren Xiaohua Zazhi 2016; 24(2): 242-247 [DOI: 10.11569/wcjd.v24.i2.242] [Reference Citation Analysis]
39 Kumar V, Chhibber S. Thalidomide: an old drug with new action. J Chemother 2011;23:326-34. [PMID: 22233815 DOI: 10.1179/joc.2011.23.6.326] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
40 Bian C, Qin W, Zhang C, Zou G, Zhu Y, Chen J, Zhao R, Wang Y, Zhe H. Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. Free Radical Biology and Medicine 2018;129:446-53. [DOI: 10.1016/j.freeradbiomed.2018.10.423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
41 McConnell EL, Liu F, Basit AW. Colonic treatments and targets: issues and opportunities. J Drug Target 2009;17:335-63. [PMID: 19555265 DOI: 10.1080/10611860902839502] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
42 Konrad A, Mähler M, Arni S, Flogerzi B, Klingelhöfer S, Seibold F. Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis 2005;20:9-17. [PMID: 15338166 DOI: 10.1007/s00384-004-0619-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
43 Tilg H, Kaser A. Antitumour necrosis factor therapy in Crohn's disease. Expert Opin Biol Ther 2002;2:715-21. [PMID: 12387670 DOI: 10.1517/14712598.2.7.715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
44 Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802-1811. [PMID: 15172781 DOI: 10.1016/s0140-6736(04)16308-3] [Cited by in Crossref: 364] [Cited by in F6Publishing: 105] [Article Influence: 20.2] [Reference Citation Analysis]
45 Lazzerini M, Villanacci V, Pellegrin MC, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Fontana M, Zuin G, Maggiore G, Bramuzzo M, Maschio M, Salemme M, Manenti S, Lorenzi L, Decorti G, Montico M, Ventura A. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Clin Gastroenterol Hepatol 2017;15:1382-1389.e1. [PMID: 28286192 DOI: 10.1016/j.cgh.2017.02.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
46 Feng R, Xu PP, Chen BL, Mao R, Zhang SH, Qiu Y, Zeng ZR, Chen MH, He Y. CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease. J Dig Dis 2020;21:98-103. [PMID: 31916702 DOI: 10.1111/1751-2980.12842] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:1079-1093. [PMID: 25858208 DOI: 10.1111/apt.13181] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
48 Park SJ, Kim HS, Yang HM, Park KW, Youn SW, Jeon SI, Kim DH, Koo BK, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB. Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery. Arterioscler Thromb Vasc Biol 2004;24:885-91. [PMID: 14988093 DOI: 10.1161/01.ATV.0000124924.21961.c3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Faubion WA, Bousvaros A. Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 2006;4:1199-213. [DOI: 10.1016/j.cgh.2006.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
50 He Y, Mao R, Chen F, Xu PP, Chen BL, Wu Y, Qiu Y, Zhang SH, Feng R, Zeng ZR, Ben-Horin S, Chen MH. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. Therap Adv Gastroenterol 2017;10:397-406. [PMID: 28507598 DOI: 10.1177/1756283X17698910] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
51 Sánchez-Capilla AD, De La Torre-Rubio P, Redondo-Cerezo E. New insights to occult gastrointestinal bleeding: From pathophysiology to therapeutics. World J Gastrointest Pathophysiol 2014; 5(3): 271-283 [PMID: 25133028 DOI: 10.4291/wjgp.v5.i3.271] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
52 Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. J Neuroinflammation. 2010;7:27. [PMID: 20398373 DOI: 10.1186/1742-2094-7-27] [Cited by in Crossref: 324] [Cited by in F6Publishing: 314] [Article Influence: 27.0] [Reference Citation Analysis]
53 Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther. 2007;25:419-427. [PMID: 17269997 DOI: 10.1111/j.1365-2036.2006.03211.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
54 Beg S, Ragunath K. Review on gastrointestinal angiodysplasia throughout the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2017;31:119-125. [PMID: 28395783 DOI: 10.1016/j.bpg.2016.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
55 Lucafò M, Franca R, Selvestrel D, Curci D, Pugnetti L, Decorti G, Stocco G. Pharmacogenetics of treatments for inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2018;14:1209-23. [PMID: 30465611 DOI: 10.1080/17425255.2018.1551876] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
56 Kirkham SE, Lindley KJ, Elawad MA, Blanshard C, Shah N. Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide. J Pediatr Gastroenterol Nutr 2006;42:585-7. [PMID: 16707986 DOI: 10.1097/01.mpg.0000215308.86287.98] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
57 Bilsborough J, Viney JL. From model to mechanism: lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease. Expert Opin Drug Discov 2006;1:69-83. [PMID: 23506033 DOI: 10.1517/17460441.1.1.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
58 Nakata K, Inagawa H, Nishizawa T, Honda T, Kohchi C, Tonomoto Y, Yoshimura H, Nagasue N, Natori S, Terada H. Inherent potential for production of tumor necrosis factor-alpha by human intestinal macrophages. Int J Colorectal Dis. 2006;21:339-347. [PMID: 16091914 DOI: 10.1007/s00384-005-0021-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
59 Kong R, Luo H, Wang N, Li J, Xu S, Chen K, Feng J, Wu L, Li S, Liu T, Lu X, Xia Y, Shi Y, Zhou Y, He W, Dai Q, Zheng Y, Lu J. Portulaca Extract Attenuates Development of Dextran Sulfate Sodium Induced Colitis in Mice through Activation of PPARγ. PPAR Res 2018;2018:6079101. [PMID: 29483924 DOI: 10.1155/2018/6079101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
60 Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008;27:111-35. [PMID: 18437602 DOI: 10.1080/08830180801911339] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
61 Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113-120. [PMID: 25075198 DOI: 10.2147/jir.s65979] [Cited by in Crossref: 172] [Cited by in F6Publishing: 83] [Article Influence: 21.5] [Reference Citation Analysis]
62 Gordon JN, Prothero JD, Thornton CA, Pickard KM, Di Sabatino A, Goggin PM, Pender SL, Macdonald TT. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease. J Crohns Colitis 2009;3:175-82. [PMID: 21172267 DOI: 10.1016/j.crohns.2009.03.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
63 Xie Y, Li D, Luan X, Jin S, Yan B, Tian F. Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells. Can J Gastroenterol Hepatol 2020;2020:8861854. [PMID: 32766176 DOI: 10.1155/2020/8861854] [Reference Citation Analysis]
64 Li T, Qiu Y, Li X, Zhuang X, Huang S, Li M, Feng R, Chen B, He Y, Zeng Z, Chen M, Zhang S. Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients. Front Med (Lausanne) 2020;7:557986. [PMID: 33240902 DOI: 10.3389/fmed.2020.557986] [Reference Citation Analysis]
65 Lügering A, Lebiedz P, Koch S, Kucharzik T. Apoptosis as a therapeutic tool in IBD? Ann N Y Acad Sci 2006;1072:62-77. [PMID: 17057191 DOI: 10.1196/annals.1326.013] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
66 Guo XG, Sun AH, Li CN, Zhang HB, Zhou XM, Xu CT, Pan BR. Effects of parenteral hyperalimentation on serum motilin, peptide YY, IgG and glycoproteins in severe ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2003; 11(2): 224-228 [DOI: 10.11569/wcjd.v11.i2.224] [Reference Citation Analysis]
67 Diamanti A, Capriati T, Papadatou B, Knafelz D, Bracci F, Corsetti T, Elia D, Torre G. The clinical implications of thalidomide in inflammatory bowel diseases. Expert Rev Clin Immunol. 2015;11:699-708. [PMID: 25865355 DOI: 10.1586/1744666x.2015.1027687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
68 Bremner A, Beattie R. Recent advances in the medical therapy of Crohn's disease in childhood. Expert Opinion on Pharmacotherapy 2007;8:2553-68. [DOI: 10.1517/14656566.8.15.2553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
69 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(6): 1441-1444 [DOI: 10.11569/wcjd.v12.i6.1441] [Reference Citation Analysis]
70 Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930-941. [PMID: 17567930 DOI: 10.1177/0091270007301623] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
71 Agarwal R, Krasilnikova AV, Raja IS, Agarwal P, Mohd Ismail N. Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats. European Journal of Pharmacology 2014;730:8-13. [DOI: 10.1016/j.ejphar.2014.02.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
72 Baert F, Vermeire S, Noman M, Van Assche G, D’ Haens G, Rutgeerts P. MANAGEMENT OF ULCERATIVE COLITIS AND CROHN’S DISEASE. Acta Clinica Belgica 2014;59:304-14. [DOI: 10.1179/acb.2004.045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
73 Parada CA, Yeh JJ, Joseph EK, Levine JD. Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat. Eur J Neurosci 2003;17:1847-52. [PMID: 12752784 DOI: 10.1046/j.1460-9568.2003.02626.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 131] [Article Influence: 6.1] [Reference Citation Analysis]
74 Tabata C, Tabata R, Takahashi Y, Nakamura K, Nakano T. Thalidomide prevents cigarette smoke extract-induced lung damage in mice. International Immunopharmacology 2015;25:511-7. [DOI: 10.1016/j.intimp.2015.02.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
75 Vermeire S, Rutgeerts P. Novel biological strategies in inflammatory bowel diseases. Inflamm Bowel Dis 2004;10 Suppl 1:S44-51. [PMID: 15168831 DOI: 10.1097/00054725-200402001-00010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
76 Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12:558-65. [PMID: 16804392 DOI: 10.1097/01.ibd.0000225337.14356.31] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 5.1] [Reference Citation Analysis]
77 Bramuzzo M, Ventura A, Martelossi S, Lazzerini M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore) 2016;95:e4239. [PMID: 27472695 DOI: 10.1097/MD.0000000000004239] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 5.6] [Reference Citation Analysis]
78 Boissé L, Van Sickle MD, Sharkey KA, Pittman QJ. Compromised neuroimmune status in rats with experimental colitis. J Physiol 2003;548:929-39. [PMID: 12640019 DOI: 10.1113/jphysiol.2002.034546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
79 Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol 2006;22:30-43. [PMID: 16319674 DOI: 10.1097/01.mog.0000196151.74819.8e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
80 Carvalho AT, Souza H, Carneiro AJ, Castelo-Branco M, Madi K, Schanaider A, Silva F, Pereira Jứnior FA, Pereira MG, Tortori C, Dines I, Carvalho J, Rocha E, Elia C. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-α, IL-12 and VEGF production. World J Gastroenterol 2007; 13(15): 2166-2173 [PMID: 17465495 DOI: 10.3748/wjg.v13.i15.2166] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
81 Feng Q, Tan HH, Ge ZZ, Gao YJ, Chen HM, Xiao SD. Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells. J Dig Dis 2014;15:85-95. [PMID: 24219762 DOI: 10.1111/1751-2980.12114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
82 Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004;53:609-12. [PMID: 15016759 DOI: 10.1136/gut.2003.029710] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 3.8] [Reference Citation Analysis]
83 Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res. 2007;149:173-186. [PMID: 17383591 DOI: 10.1016/j.trsl.2006.11.009] [Cited by in Crossref: 150] [Cited by in F6Publishing: 150] [Article Influence: 10.0] [Reference Citation Analysis]
84 Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol. 2007;13:5979-5984. [PMID: 18023086 DOI: 10.3748/wjg.13.5979] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
85 Osterman MT, Lichtenstein GR. Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2007;10:195-207. [PMID: 17547858 DOI: 10.1007/s11938-007-0013-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
86 Bauditz J, Lochs H. Angiogenesis and vascular malformations: Antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13(45): 5979-5984 [DOI: 10.3748/wjg.v13.i45.5979] [Reference Citation Analysis]
87 Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003;79:127-32. [PMID: 12697909 DOI: 10.1136/pmj.79.929.127] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
88 Lazzerini M, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Lorusso M, Mangiantini F, Fontana M, Zuin G, Palla G, Maggiore G, Bramuzzo M, Pellegrin MC, Maschio M, Villanacci V, Manenti S, Decorti G, De Iudicibus S, Paparazzo R, Montico M, Ventura A. Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial. Inflamm Bowel Dis 2015;21:1739-49. [PMID: 26185909 DOI: 10.1097/MIB.0000000000000437] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
89 Collij V, Festen EAM, Alberts R, Weersma RK. Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information: . Inflammatory Bowel Diseases 2016;22:2562-70. [DOI: 10.1097/mib.0000000000000912] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 Mazzoccoli L, Cadoso SH, Amarante GW, de Souza MV, Domingues R, Machado MA, de Almeida MV, Teixeira HC. Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10. Biomedicine & Pharmacotherapy 2012;66:323-9. [DOI: 10.1016/j.biopha.2012.05.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
91 Santos JRS, Vendramini DL, Nery JADC, Avelleira JCR. Etanercept in erythema nodosum leprosum. An Bras Dermatol 2017;92:575-7. [PMID: 28954119 DOI: 10.1590/abd1806-4841.20175471] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
92 Fantini MC, Becker C, Kiesslich R, Neurath MF. Drug insight: novel small molecules and drugs for immunosuppression. Nat Clin Pract Gastroenterol Hepatol 2006;3:633-44. [PMID: 17068501 DOI: 10.1038/ncpgasthep0611] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
93 Scribano ML, Cantoro L, Marrollo M, Cosintino R, Kohn A. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review. J Clin Gastroenterol 2014;48:530-3. [PMID: 24667589 DOI: 10.1097/MCG.0000000000000122] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
94 Rehman W, Arfons LM, Lazarus HM. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther Adv Hematol 2011;2:291-308. [PMID: 23556097 DOI: 10.1177/2040620711413165] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
95 Poturoglu S, Kaymakoglu S, Gurel Polat N, Ibrisim D, Ahishali E, Akyuz F, Badur S, Demir K, Mungan Z. A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease. Scand J Clin Lab Invest 2009;69:696-702. [PMID: 19452347 DOI: 10.3109/00365510902989075] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
96 Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn’s disease resistant to standard therapies. Aliment Pharmacol Ther. 2007;25:557-567. [PMID: 17305756 DOI: 10.1111/j.1365-2036.2006.03239.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]